{"id":"W2984886575","doi":"10.1136/ijgc-2019-000623","title":"Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety","year":2019,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Foundation Medicine; National Institute for Health and Care Research; Wellcome Trust; Clovis Oncology; University College London; Wellcome","keywords":"Medicine; PARP inhibitor; Ovarian cancer; Poly ADP ribose polymerase; Polymerase; Cancer research; BRCA mutation; Olaparib; Oncology; Internal medicine; Pharmacology; Cancer; Gene; Genetics; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002584483,0.0002425402,0.0009528483,0.000332898,0.000135337,0.00086143,0.0004294053,0.0003668224,0.0009520439],"category_scores_gemma":[0.001950734,0.0001730885,0.0009873144,0.0004527941,0.000219086,0.0004213804,0.0001904551,0.001071036,0.0001695017],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007781646,"about_ca_system_score_gemma":0.0007821796,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007146802,"about_ca_topic_score_gemma":0.003210424,"domain_scores_codex":[0.9992757,0.0003334507,0.00008721423,0.00008140082,0.0001694332,0.0000528495],"domain_scores_gemma":[0.9982863,0.0005645542,0.0005632262,0.0001206745,0.0002980312,0.000167214],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.06857283,0.002552547,0.0704124,0.003764868,0.006118121,0.0002419611,0.0002708066,0.002202105,0.0266693,0.0005036856,0.01189142,0.8067999],"study_design_scores_gemma":[0.07643895,0.2047199,0.5500483,0.002334861,0.01938528,0.00324435,0.0003510037,0.007829117,0.03201509,0.001476564,0.101988,0.000168605],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8451927,0.1404369,0.001272494,0.00288166,0.0002322896,0.0004761443,0.001973541,0.0001214693,0.007412938],"genre_scores_gemma":[0.965763,0.02633804,0.001523588,0.002354038,0.000351626,0.0002171216,0.002387536,0.0000253583,0.001039721],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002584483,"threshold_uncertainty_score":0.01366824,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01021651370825646,"score_gpt":0.2947875185163555,"score_spread":0.284571004808099,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}